Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Chemocentryx Inc (CCXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 576,502
  • Shares Outstanding, K 50,526
  • Annual Sales, $ 42,880 K
  • Annual Income, $ -37,970 K
  • 60-Month Beta 1.28
  • Price/Sales 12.70
  • Price/Cash Flow N/A
  • Price/Book 36.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.23
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.23
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.91 +11.71%
on 03/08/19
11.66 -5.06%
on 03/19/19
-0.02 (-0.18%)
since 02/20/19
3-Month
9.44 +17.27%
on 12/21/18
12.81 -13.58%
on 01/18/19
+0.97 (+9.60%)
since 12/20/18
52-Week
9.07 +22.05%
on 11/20/18
15.08 -26.59%
on 03/21/18
-3.19 (-22.37%)
since 03/20/18

Most Recent Stories

More News
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CCXI , STML , CYTK , NBIX , DVAX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CYTK : 9.88 (+15.42%)
STML : 12.94 (-3.14%)
CCXI : 11.12 (-2.54%)
ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session

ChemoCentryx (CCXI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AITB : 4.7100 (+2.39%)
CCXI : 11.12 (-2.54%)
ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 22.22% and -2.14%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

CCXI : 11.12 (-2.54%)
ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

-- Strong Progress Across Company's Orphan Disease Franchise of Novel Renal and Dermal Therapeutics --

CCXI : 11.12 (-2.54%)
ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market close on Monday, March 11, 2019. ChemoCentryx executive management...

CCXI : 11.12 (-2.54%)
New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ellie Mae, Inc. (NYSE:ELLI),...

BRS : 1.34 (+13.56%)
TDC : 45.26 (-6.33%)
ELLI : 98.66 (-0.05%)
SPOT : 141.60 (+0.04%)
AGFS : 3.59 (+2.87%)
CCXI : 11.12 (-2.54%)
ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday,...

CCXI : 11.12 (-2.54%)
ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday,...

JPM : 106.13 (-0.63%)
CCXI : 11.12 (-2.54%)
ChemoCentryx's Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference

-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo --

CCXI : 11.12 (-2.54%)
New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ralph Lauren Corporation...

SXCP : 13.02 (-2.18%)
PRAA : 26.56 (-1.78%)
DK : 35.52 (-1.22%)
RL : 122.61 (-1.76%)
CECE : 7.32 (-3.17%)
CCXI : 11.12 (-2.54%)
SXC : 8.95 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CCXI with:

Business Summary

ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

See More

Key Turning Points

2nd Resistance Point 12.19
1st Resistance Point 11.80
Last Price 11.12
1st Support Level 10.88
2nd Support Level 10.35

See More

52-Week High 15.08
Fibonacci 61.8% 12.78
Fibonacci 50% 12.07
Fibonacci 38.2% 11.37
Last Price 11.12
52-Week Low 9.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar